Lower Gastrointestinal Bleeding Because of Kasabach-Merritt Syndrome Showing an Impressive Response to Sirolimus

Jorge Sandelis Pérez, MD1, Dahima Cintrón, MD2, Alexandra Deyá-Quinquilla, MD3, Josselyn Molina, MD3, Verónica Belay Pagán, MD4, Pedro Vargas-Otero, MD1, Enid Rivera, MD3, Maribel Tirado-Gómez, MD3, Eileen Pacheco, MD3, and Pablo Costas, MD4

1Internal Medicine Department, University of Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico
2Internal Medicine/Pediatrics Residency, University of Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico
3Division of Hematology-Oncology, Internal Medicine Department, University of Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico
4Division of Gastroenterology and Hepatology, Internal Medicine Department, University of Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico
5Division of Hematology-Oncology, Pediatrics Department, University of Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico

ABSTRACT

Kasabach-Merritt syndrome is a rare but life-threatening disease in which a rapidly growing vascular tumor induces localized intravascular coagulation, causing thrombocytopenia, microangiopathic hemolytic anemia, and consumption coagulopathy. It presents mainly in infants and young children. We present an adult with recurrent and severe lower gastrointestinal bleeding due to Kasabach-Merritt syndrome, treated successfully with sirolimus after multiple other failed interventions.

INTRODUCTION

Kasabach-Merritt syndrome (KMS) is a syndrome of intravascular coagulation that occurs in the setting of rapidly growing vascular tumors. The aberrant anatomy, and the endothelial dysfunction of the intratumoral vessels, causes abnormal activation of the coagulation pathway leading to thrombocytopenia, microangiopathic hemolytic anemia, and consumption coagulopathy. The vascular tumors primarily associated with KMS are the Kaposiform hemangioendothelioma and the tufted angioma.1–4 It was first described in 1940 in a male infant; only approximately 200 cases have been reported in the literature, most of which (80%) are diagnosed within the first year of life.5,6 The mortality rate of KMS is 20%–40%, mainly because of intractable bleeding caused by the consumption coagulopathy.4,7 The lack of consensus to guide therapy makes the management much more challenging.

CASE REPORT

A 21-year-old woman with a presumptive diagnosis of Klippel-Trenaunay syndrome was transferred from another institution because of severe lower gastrointestinal bleeding (LGIB). She was born with a large capillary and venous malformation extending from the gluteus maximus and pelvis to the right foot, accompanied by congenital right lower limb overgrowth and numerous intestinal vascular tumors, causing multiple episodes of LGIB over the years (Figure 1). At the age of 4, an effort to debulk the limb tumor was unsuccessful because of severe intraoperative bleeding. Previous attempts with treatments such as propranolol, corticosteroids, interferon-gamma, vincristine, aminocaproic acid, and embolization and partial elective jejuno colectomy at 10 and 17 years old, respectively, were ineffective. The patient had no pediatric follow-up since, and at 20 years old, she had a severe episode of bleeding and underwent terminal ileum and ceco-ascending colon resection (20 cm), with partial jejunal resection (9.5 cm): Both surgical specimens revealed the presence of capillary type vascular malformations.
After 1 year without bleeding, she went to another institution complaining of a 3-week history of bright red blood mixed with brown stool, associated with pallor, palpitations, and exertional dyspnea. Laboratory test results revealed a hemoglobin of 5.9 g/dL, physical therapy: 23.2 seconds, partial thromboplastin time: 30 seconds, international normalized ratio: 2.02, severe hypofibrinogenemia (<50 mg/dL), and thrombocytopenia (59 k/uL). The patient was admitted to the intensive care unit with symptomatic anemia due to LGIB and a clinical diagnosis of KMS.

During hospitalization, the patient received multiple units of packed red blood cells, fresh frozen plasma, and cryoprecipitate. A colonoscopy was advanced to the ileotransverse anastomosis, revealing vascular tumors; no hemostasis was attempted, given the patient’s coagulopathic state and especially because it was not considered to be the etiology of the bleeding (Figure 2). An upper endoscopy and a gastrointestinal bleeding scan also failed to reveal the bleeding site. Abdominopelvic computed tomography enterography was pertinent for at least 2 intraluminal vascular blushes within the small bowel loops of the right lumbar region of the abdomen, most probably representing additional intraluminal vascular malformations (Figure 3).

An intraoperative enteroscopy was considered. However, a multidisciplinary team recommended against embolization and further surgeries, given the previous history of recurrence and the risk of short bowel syndrome. The patient improved with administration of anti-inhibitor coagulant complex; however, after discontinuation of coagulation factor replacement, and each time enteral feeding was restarted, the LGIB reoccurred.

Given the severe clinical presentation refractory to all forms of standard treatment, we decided to administer sirolimus, at a dose of 0.8 mg/m². The patient was informed of risks and benefits, and she consented to treatment. Complete resolution of bleeding was observed within 48 hours of the first dose. In addition, hemoglobin improved (10.6 g/dL) and platelet count (205 k/uL), and fibrinogen levels (98 mg/dL). After 48 days of hospitalization, the patient was discharged home. One year later, the patient continues taking the sirolimus and has maintained an appropriate hemoglobin level without evidence of new bleeding or coagulopathy (Table 1).

DISCUSSION

KMS involves activation and consumption of platelets and clotting factors inside vascular malformations, giving rise to
consumption coagulopathy and bleeding. Its management primarily should be directed to hastening vascular lesion regression, responsible for the coagulopathy, and supportive measures to maintain hemostasis. Several treatments have been used, including surgery, radiotherapy, vascular embolization, and pharmacology with variable rates of effectiveness, and as a result, standard and definitive guidelines for the treatment of KMS have not yet been established.

Surgical intervention is rarely feasible, given the infiltrative nature of the associated tumor and existing coagulopathy, as evidenced in this case. It is the treatment of choice for small, localized tumors and is usually followed by the resolution of thrombocytopenia and coagulopathy. If a lesion is inoperable, an interventional radiologic procedure to embolize the tumor or local administration of sclerosing agents may be attempted. In our case, radiological embolization was not attempted because of critical location and extensive limb involvement.

Several pharmacological options reported in the literature have demonstrated some benefits but are not approved by the US Food and Drug Administration. For large, nonresectable tumors, 2 alternatives are the administration of vincristine 0.05 mg/kg intravenous weekly plus prednisone 2 mg/kg orally daily or sirolimus 0.8 mg/m² orally every 12 hours with or without prednisone.

Sirolimus is believed to exert its beneficial effect by blocking the mammalian target of rapamycin signaling pathway, which is activated in response to vascular endothelial growth factor receptor attaching to its ligand. This pathway is essential for the proliferation of endothelial cells of vascular tumors, and blocking it using sirolimus may promote shrinkage of the lesion and improvement of coagulopathy.

Owing to its oral administration and growing literature attesting to the safety and effectiveness of sirolimus, including a more rapid resolution of the coagulopathy of KMS, most physicians
are using sirolimus as the first-line treatment for KMS. It is essential that sirolimus through serum levels be monitored regularly and must not exceed 10–13 ng/mL. However, how long the patient should be under treatment is not yet established in the literature. This is the first case of KMS successfully treated with sirolimus in the largest supratertiary hospital in Puerto Rico. This experience demonstrated the efficacy of sirolimus and could contribute to developing appropriate guidelines for the management of these patients.

DISCLOSURES

Author contributions: All authors contributed equally to this manuscript. JS Pérez is the article guarantor.

Financial disclosure: None to report.

Previous presentation: This case was presented at the American College of Gastroenterology Annual Scientific Meeting, October 23–28, 2020; Virtual.

Informed consent was obtained for this case report.

Received December 7, 2020; Accepted May 7, 2021

REFERENCES

1. Lewis D, Vaidya R. Kasabach Merritt Syndrome [Updated 2019 Mar 13]. In: StatPearls [Internet]. StatPearls Publishing: Treasure Island (FL), 2019. Available at: https://www.ncbi.nlm.nih.gov/books/NBK519053/.

2. Mahajan P, Margolin J, Iacobas I. Kasabach-Merritt phenomenon: Classic presentation and management options. Clin Med Insights Blood Disord. 2017.

3. Haisley-Royster C, Enjolras O, Frieden IJ, et al. Kasabach-merritt phenomenon: A retrospective study of treatment with vincristine. J Pediatr Hematol Oncol. 2002;24(6):150–450 × 10^3/L

4. Adams D. Kasabach-Merritt phenomenon. National Organization for Rare Disorders (NORD); 2008. Available at: http://www.rarediseases.org/search/rdbdetail_abstract.html?disname=Kasabach-Merritt%20phenomenon. Accessed January 13, 2020.

5. Arunachalam P, Kumar VR, Swathi D. Kasabach-Merritt syndrome with large cutaneous vascular tumors. J Indian Assoc Pediatr Surg. 2012;17(1):33–6.

6. Hesselmann S, Micke O, Marquardt T, et al. Kasabach-Merritt syndrome: A review of the therapeutic options and a case report of successful treatment with radiotherapy and interferon alpha. Br J Radiol. 2002;75(880):180–4.

7. Szlachetka DM. Kasabach-Merritt syndrome: A case review. Neonatal Netw. 1998;17(1):7–15.

8. Boccara O, Fraitag S, Lasne D, et al. Kaposiform haemangioendothelioma-spectrum lesions with kasabach-merritt phenomenon: Retrospective analysis and long-term outcome. Acta Derm Venereol. 2016;96(1):77–81.

9. Kim JA, Choi YB, Yi ES, et al. Excellent outcome of medical treatment for kasabach-merritt syndrome: A single-center experience. Blood Res. 2016;51(4):256–60.

Copyright: © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Table 1. Comparative of laboratory results before and after sirolimus

| Laboratory tests | At admission | At discharge (after sirolimus) | One year after sirolimus | References |
|------------------|-------------|-------------------------------|--------------------------|------------|
| WBC              | 6.7         | 8.5                           | 7.12                     | 4–11 × 10^3/μL |
| Hgb              | 5.9L        | 10.6L                         | 13.2                     | 12–14.5 g/dL |
| Htc              | 17.3L       | 33.6L                         | 40.0                     | 35%–45%    |
| Platelets        | 5 L         | 205                           | 222                      | 150–450 × 10^3/L |
| PT               | 23.2H       | 12.1                          | 10.4                     | 10.0–13.9 s |
| INR              | 2.02H       | 1.0                           | 0.99                     | 0.86–1.20  |
| PTT              | 30.0        | 30.0                          | 28                       | 25.3–32.8 s |
| Fibrinogen       | <50         | 98L                           | 117L                     | 174–343 mg/dL |

Hgb, hemoglobin; INR, international normalized ratio; PTT, partial thromboplastin time; WBC, white blood cell.